Nav: Home

Corneal collagen cross-linking for keratoconus: Now data provide hint of benefit

November 30, 2016

In patients with keratoconus the cornea of the eye begins to bulge. So-called corneal collagen cross-linking aims to halt this process. In this procedure, the cornea is stiffened through locally applied vitamin B2 in combination with UVA radiation. The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated what advantages or disadvantages this procedure can have for patients and published its final report on 15 November.

Additional available data resulting from a query to the authors of an Australian study now show a hint of a benefit of corneal collagen cross-linking versus purely symptomatic treatment. But the data also provide a hint of harm. With regard to the comparison of different variants of the procedure with each other, the data only provide a hint of an advantage of the transepithelial procedure versus the conventional one. However, overall the evidence is still insufficient.

Stiffening of tissue aims to halt progression

Keratoconus is a non-inflammatory tissue disorder of the cornea of the eye, typically already occurring in adolescents and young adults. The cornea begins to bulge, which may not only impair vision but, among other things, may also cause severe pain. In the advanced stage, corneal deformation can no longer be compensated with glasses or contact lenses; then the only option may be a corneal transplant.

Corneal collagen cross-linking is the first and so far only treatment option to halt the progression of corneal deformation in keratoconus. In the conventional procedure the cornea is mechanically exposed and treated with vitamin B2 (riboflavin) and UVA light, which aims to link the collagen fibrils, thus "stiffening" the cornea.

About a third of the studies cannot be used

The Federal Joint Committee (G-BA) commissioned IQWiG to assess the benefit of this procedure compared with purely symptomatic treatment or with other types of corneal collagen cross-linking.

For the final report, IQWiG identified a total of 19 randomized controlled trials that are in principle suited to answer 1 of the 2 research questions. However, about a third of these studies could not be used. This was mainly due to the fact that the treatment results were not analysed in a manner appropriate to the respective study design.

Results could be biased

In some studies only one eye of patients was randomly assigned to the treatment groups; in other studies, this applied to both eyes. Both study designs can be meaningful. However, if both eyes of a patient are considered in the study, then statistical tests or models have to be applied in the analysis to account for data dependency. But this was not the case, meaning the results could be biased.

Australian author group submitted IPD

In principle, IQWiG can also conduct appropriate analyses post hoc. However, for this purpose further information on the studies as well as results data are required (individual patient data, IPD). The corresponding requests to the study authors were initially unsuccessful - most author groups did not respond at all; some stated that they were not prepared to provide their data.

However, after publication of the preliminary report IQWiG was able to conclude a contract with an Australian study group, which regulates data use in detail. On the basis of IPD subsequently submitted to IQWiG, it was possible to consider this study in the assessment.

Advantage for uncorrected visual acuity, but also occurrence of side effects

The results data of this author group show that, compared with purely symptomatic treatment, conventional corneal collagen cross-linking offers an advantage for vision. However, this applies only to "uncorrected visual acuity" (i.e. vision without corrective measures) not for "best-corrected visual acuity" (i.e. vision with corrective measures, e.g. by means of glasses).

In addition, the results on side effects are unfavourable for conventional corneal collagen cross-linking. This is because corneal haze and erosions occur more often than with purely symptomatic treatment. But this mainly refers to transient and reversible side effects.

IQWiG thus sees both a hint of benefit (uncorrected visual acuity) and harm (side effects) from treatment.

Vision better with transepithelial procedure

For the second question, that is, the comparison of variants of corneal collagen cross-linking with each other, the data available showed relevant differences only between the transepithelial procedure and the conventional one. Here, the data provide a hint of greater benefit of the transepithelial procedure for best-corrected visual acuity, but not for uncorrected visual acuity. In addition, a hint of lesser harm can be inferred from the study data, as the pain did not last as long after this procedure as it did after the conventional one.

However, it cannot be inferred from the data whether the transepithelial procedure also shows benefit or harm versus purely symptomatic treatment.

Further study results expected soon

The data from the Australian study were robust enough to be considered in the analysis. However, the qualitative certainty of their results is still to be classified as moderate. And beyond this one study, the evidence is generally still unsatisfactory.

IQWiG thus recommends performing a conclusive assessment of corneal collagen cross-linking only when the results of completed but still unpublished studies or currently ongoing studies become available; IQWiG identified 26 such studies.

It is incomprehensible that some studies completed or discontinued some time ago have not been published - in part, this is not even intended. The picture that both researchers, as well as clinicians and patients, could obtain of corneal collagen cross-linking will thus in any event remain incomplete.

Process of report production

IQWiG published the preliminary results in the form of the preliminary report in January 2016 and interested parties were invited to submit comments. At the end of the commenting procedure, the preliminary report was revised and sent as a final report to the commissioning agency in September 2016. The written comments submitted were published in a separate document together with the final report. The report was produced in collaboration with external experts.
-end-
An English-language extract of the final report will be available soon. If you would like to be informed when this document is available, please send an e-mail to info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Side Effects Articles:

Popular prostate drug linked to serious side effects
Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction.
Previously unpublished trial data explain effects and side effects of key MS drug
Through a Freedom of Information request to the European Medicines Agency, researchers from Queen Mary University of London (QMUL) gained access to the phase III trial datasets of Alemtuzumab, and publish new insights (JAMA Neurology) into the drastic response of the immune system in patients with MS.
Painkillers without dangerous side effects
Researchers from Charité - Universitätsmedizin Berlin have discovered a new way of developing painkillers.
Measuring patients' muscles to predict chemotherapy side effects
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report in the journal Clinical Cancer Research that measuring patients' muscle mass and quality could potentially help doctors better identify patients at high risk for toxic side effects that could require hospitalizations.
Ground-breaking research on the side effects of therapy
While many people who suffer from depression and anxiety are helped by seeing a psychologist, others don't get better or actually get worse.
Naturally occurring symptoms may be mistaken for tamoxifen side-effects
Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data presented at the San Antonio Breast Cancer Symposium.
An appetite suppressant with side effects
Neurogeneticists from the University of Würzburg have discovered a peptide in Drosophila that has a strong impact on the fly's feeding and sleeping habits.
Dopamine receptor blockade seen as cause for antipsychotic drug side-effects
University of California, Irvine scientists led by Emiliana Borrelli and colleagues have discovered the key cellular mechanism that underlies the antipsychotic-induced parkinsonism -- which includes involuntary movements, tremors and other severe physical conditions.
Predicting potential pharma side effects
A computer program that can predict whether or not a given pharmaceutical will have worrying side effects has been developed by researchers in the USA.
Reduced side effects from ECT for those with severe depression
Despite its effectiveness, use of ECT remains limited due to concerns about side effects.

Related Side Effects Reading:

Side Effects May Vary
by Julie Murphy (Author)

Managing the Side Effects of Psychotropic Medications
by Joseph F. Goldberg (Author), Carrie L. Ernst (Author)

Side Effects: A Gripping Serial Killer Thriller (Maggie Allen FBI Thriller Book 1)
by Mind Mess Press

Side Effects: A Novel
by Bantam

What Works May Hurt―Side Effects in Education
by Yong Zhao (Author)

The Five Side Effects of Kindness: This Book Will Make You Feel Better, Be Happier & Live Longer
by David R. Hamilton PHD (Author)

Side Effects Of Loving You 2: A Matin Novel
by K. Maddison Publications

Side Effects Of Loving You: A Matin Novel
by K. Maddison Publications

Side Effects of Psychiatric Medications: Prevention, Assessment, and Management (Simple and Practical)
by Rajnish Mago M.D. (Author)

The Side Effects Bible: The Dietary Solution To The Unwanted Side Effects Of Common Medications
by Frederic Vagnini M.D. (Author), Barry Fox Ph.D. (Author)

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".